Endo Pharmaceuticals Holdings (NASDAQ:ENDP) will report earnings before markets open on Tuesday, May 7th. Endo Pharmaceuticals Holdings Inc. is a specialty pharmaceutical company with products that provide pain management. The Company researches, develops, produces, and markets both branded and generic pharmaceuticals. Endo’s products include Percocet, Percodan, and Lidoderm.
Here is your Cheat Sheet to Endo Pharmaceuticals Holdings Earnings:
Earnings Expectations: Analysts expect earnings of $1.09 per share on revenues of $738.21 million.
Analysts have a more negative outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings has fallen from a profit of $1.23 to a profit $1.21. For the current year, the average estimate is a profit of $4.5, which is worse than the estimate ninety days ago.
Here’s how Endo Pharmaceuticals Holdings has been performing on an annual basis:
|Revenue ($) in millions||1,261||1,461||1,716||2,730||3,027|
|Diluted EPS ($)||2.06||2.27||2.20||1.55||-6.40|
Next, our CHEAT SHEET investing framework asks us to drill down to the recent quarterly data:
|Quarter||Dec. 31, 2011||Mar. 31, 2012||Jun. 30, 2012||Sep. 30, 2012||Dec. 31, 2012|
|Revenue ($) in millions||803.41||690.63||785.19||750.48||801.06|
|Diluted EPS ($)||0.3039||-0.75||0.08||0.45||-6.349|
Endo Pharmaceuticals Holdings has beat analyst estimates 3 times in the past four quarters. Shareholders could expect a boost if the company beats estimates.
“E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our successful CHEAT SHEET investing framework. Don’t waste another minute – click here to discover our CHEAT SHEET stock picks now!
(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at] wallstcheatsheet.com)